The results from a prespecified subproject of the first 500 randomized patients within the TAXIS study show that a larger proportion of patients with Her2+ BC or TNBC underwent NACT and that NACT administration increased over the study period [139] (LoE III). This evidence concerns the gene ERBB2 and breast cancer.